{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:51:02Z","timestamp":1787316662965,"version":"build-2736575974"},"reference-count":115,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["AI154722"],"award-info":[{"award-number":["AI154722"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX003895"],"award-info":[{"award-number":["I01BX003895"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jncc.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:46:19Z","timestamp":1751917579000},"page":"441-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuromuscular complications associated with cancer immunotherapy"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5370-7606","authenticated-orcid":false,"given":"Ge","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lomen-Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7422-3520","authenticated-orcid":false,"given":"Tianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jncc.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy\u2013inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000001259","article-title":"Central nervous system adverse events of immune checkpoint inhibitors","volume":"37","author":"Farina","year":"2024","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","article-title":"Neurological sequelae of cancer immunotherapies and targeted therapies","volume":"17","author":"Wick","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CJI.0000000000000364","article-title":"Immune checkpoint inhibitor-related Guillain-Barr\u00e9 Syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"2021","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100791","article-title":"Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature","volume":"8","author":"Boutros","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40487-019-0096-8","article-title":"A review of immune-mediated adverse events in melanoma","volume":"7","author":"Kennedy","year":"2019","journal-title":"Oncol Ther"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10072-021-05561-z","article-title":"Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience","volume":"43","author":"Diamanti","year":"2022","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.21873\/invivo.12640","article-title":"Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment","volume":"35","author":"Kuboki","year":"2021","journal-title":"In Vivo (Brooklyn)"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.jncc.2025.05.004_bib0017","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic syndromes involving the nervous system","volume":"349","author":"Darnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.004_bib0018","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"85","key":"10.1016\/j.jncc.2025.05.004_bib0019","doi-asserted-by":"crossref","first-page":"eadd1591","DOI":"10.1126\/sciimmunol.add1591","article-title":"Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis","volume":"8","author":"Wang","year":"2023","journal-title":"Sci Immunol"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-0011","article-title":"Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis","volume":"12","author":"Siddiqui","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0022","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa051","article-title":"Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: a case report","volume":"4","author":"Szuchan","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.jncc.2025.05.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1804703","article-title":"Tropomyosin autoantibodies associated with checkpoint inhibitor myositis","volume":"9","author":"Zaenker","year":"2020","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0029","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41467-020-20874-x","article-title":"CTLA-4 expression by B-1a B cells is essential for immune tolerance","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"issue":"19","key":"10.1016\/j.jncc.2025.05.004_bib0031","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.18632\/oncotarget.22976","article-title":"Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1\/PD-L1 pathway","volume":"9","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0032","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0033","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/jpm12060888","article-title":"CD21lo B cells could be a potential predictor of immune-related adverse events in renal cell carcinoma","volume":"12","author":"Nishimura","year":"2022","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0034","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.004_bib0035","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200177","article-title":"Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0037","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10072-023-07190-0","article-title":"Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors","volume":"45","author":"Fionda","year":"2024","journal-title":"Neurol Sci"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.004_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.004_bib0041","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.jncc.2025.05.004_bib0043","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0044","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/eji.201444960","article-title":"GM-CSF promotes migration of human monocytes across the blood brain barrier","volume":"45","author":"Vogel","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152706","article-title":"TNF-\u03b1 evokes blood-brain barrier dysfunction through activation of rho-kinase and neurokinin 1 receptor","volume":"228","author":"Gao","year":"2023","journal-title":"Immunobiology"},{"issue":"Suppl_1","key":"10.1016\/j.jncc.2025.05.004_bib0046","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.004_bib0047","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/icb.2017.56","article-title":"IFN-\u03b3 promotes transendothelial migration of CD4+ T cells across the blood-brain barrier","volume":"95","author":"Sonar","year":"2017","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0048","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0049","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"issue":"48","key":"10.1016\/j.jncc.2025.05.004_bib0050","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0051","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/STROKEAHA.119.028638","article-title":"IL (Interleukin)-15 bridges astrocyte-microglia crosstalk and exacerbates brain injury following intracerebral hemorrhage","volume":"51","author":"Shi","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jncc.2025.05.004_bib0052","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-2094-5-7","article-title":"The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective","volume":"5","author":"Shaftel","year":"2008","journal-title":"J Neuroinflammation"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.004_bib0053","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.3390\/ijms24097960","article-title":"Autoimmune neuroinflammatory diseases: role of interleukins","volume":"24","author":"Khan","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0054","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"46","key":"10.1016\/j.jncc.2025.05.004_bib0055","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0056","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"Suppl 5","key":"10.1016\/j.jncc.2025.05.004_bib0057","first-page":"v108","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0058","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neurooncol"},{"issue":"29","key":"10.1016\/j.jncc.2025.05.004_bib0059","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026673","article-title":"The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: a meta-analysis","volume":"100","author":"Huang","year":"2021","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0061","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1667\/RADE-22-00061.1","article-title":"PD-1 inhibitor enhanced radiosensitivity by reactivating T cells and inducing G2\/M phase arrest in esophageal squamous cell carcinoma","volume":"198","author":"Hao","year":"2022","journal-title":"Radiat Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0062","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"issue":"29","key":"10.1016\/j.jncc.2025.05.004_bib0063","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205378119","article-title":"Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events","volume":"119","author":"Tsukamoto","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.jncc.2025.05.004_bib0064","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0065","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/onco.13740","article-title":"Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018","volume":"26","author":"Molina","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jncc.2025.05.004_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.jncc.2025.05.004_bib0067","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jncc.2025.05.004_bib0068","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005611","article-title":"Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?","volume":"10","author":"Vos","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/1120009X.2023.2290348","article-title":"The relationship between statin administration timing and survival outcomes in patients with cancer receiving immune checkpoint blockade","volume":"36","author":"Wang","year":"2024","journal-title":"J Chemother"},{"key":"10.1016\/j.jncc.2025.05.004_bib0071","article-title":"Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.004_bib0072","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1634\/theoncologist.2019-0911","article-title":"Statin intolerance, anti-HMGCR antibodies, and immune checkpoint inhibitor-associated myositis: a ``two-hit'' autoimmune toxicity or clinical predisposition?","volume":"25","author":"von Itzstein","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0073","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","article-title":"Myositis as a neuromuscular complication of immune checkpoint inhibitors","volume":"120","author":"Vermeulen","year":"2020","journal-title":"Acta Neurol Belg"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.004_bib0074","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0075","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.jncc.2025.05.004_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2022.100442","article-title":"Checkpoint inhibitor induced myositis - the value of MRI STIR","volume":"30","author":"Erritz\u00f8e-Jervild","year":"2023","journal-title":"ENeurologicalSci"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0078","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.004_bib0079","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.004_bib0080","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Ishikawa","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jncc.2025.05.004_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1206631","article-title":"Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0082","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","article-title":"Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy","volume":"9","author":"Ma","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0083","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.980181","article-title":"Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors","volume":"12","author":"Young","year":"2022","journal-title":"Front Oncol"},{"issue":"42","key":"10.1016\/j.jncc.2025.05.004_bib0084","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jncc.2025.05.004_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1199195","article-title":"Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review","volume":"13","author":"Xiong","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0086","doi-asserted-by":"crossref","first-page":"fcad169","DOI":"10.1093\/braincomms\/fcad169","article-title":"Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity","volume":"5","author":"Farina","year":"2023","journal-title":"Brain Commun"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.004_bib0087","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"issue":"5\u20136","key":"10.1016\/j.jncc.2025.05.004_bib0088","first-page":"203","article-title":"Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barr\u00e9 Syndrome: a double-blind, randomized clinical trial","volume":"41","author":"Haridy","year":"2023","journal-title":"Restor Neurol Neurosci"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0089","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mus.24960","article-title":"Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis","volume":"53","author":"Furlan","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jncc.2025.05.004_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111761","article-title":"Multi-centers experience using therapeutic plasma exchange for corticosteroid\/tocilizumab-refractory cytokine release syndrome following CAR-T therapy","volume":"130","author":"Pu","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0091","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an ``enigma'' of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0092","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0093","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0000000000000382","article-title":"Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis","volume":"29","author":"Singer","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.004_bib0094","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jncc.2025.05.004_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1168614","article-title":"Case report: immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab","volume":"3","author":"Qureshi","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0096","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1338899","article-title":"Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma","volume":"15","author":"Farina","year":"2024","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0097","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0098","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0099","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neurol.2023.03.015","article-title":"Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents","volume":"179","author":"Bompaire","year":"2023","journal-title":"Rev Neurol (Paris)"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.004_bib0100","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4049\/jimmunol.2000455","article-title":"Abatacept promotes regulatory B cell functions, enhancing their ability to reduce the Th1 response in rheumatoid arthritis patients through the production of IL-10 and TGF-\u03b2","volume":"207","author":"Carvajal Alegria","year":"2021","journal-title":"J Immunol"},{"issue":"SI2","key":"10.1016\/j.jncc.2025.05.004_bib0101","doi-asserted-by":"crossref","first-page":"SI195","DOI":"10.1093\/rheumatology\/keae025","article-title":"Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO\/PRCSG registry","volume":"63","author":"Lovell","year":"2024","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.jncc.2025.05.004_bib0102","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.004_bib0103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.004_bib0104","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.004_bib0106","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.it.2009.09.006","article-title":"CD24-siglec G\/10 discriminates danger- from pathogen-associated molecular patterns","volume":"30","author":"Liu","year":"2009","journal-title":"Trends Immunol"},{"issue":"5922","key":"10.1016\/j.jncc.2025.05.004_bib0107","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1126\/science.1168988","article-title":"CD24 and siglec-10 selectively repress tissue damage-induced immune responses","volume":"323","author":"Chen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jncc.2025.05.004_bib0108","article-title":"CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0109","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41392-022-01030-x","article-title":"CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.004_bib0110","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.004_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.004_bib0112","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.004_bib0113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.004_bib0114","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jtho.2020.05.007","article-title":"Multidisciplinary approach of immune checkpoint inhibitor-related pneumonitis: a key to address knowledge and management gaps","volume":"15","author":"P\u00e9rol","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jncc.2025.05.004_bib0115","series-title":"Abstract presented at: Myasthenia Gravis Foundation of America Scientific Session","article-title":"A retrospective case series of myasthenia gravis associated with immune checkpoint inhibitors","author":"Xiong","year":"2024"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:33:48Z","timestamp":1762641228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266700542500081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":115,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S266700542500081X"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.05.004","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromuscular complications associated with cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}